The DNM-conjugated TFOs can inhibit the c-myc gene transcription in vitro and reduce c-myc promoter activity in prostate and breast cancer cells while less effective against normal cells (Carbone et al., 2004; Napoli et al., 2006). The gene discussed is MYC; the disease is breast carcinoma.